Abstract
Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV) infection. Currently, treatment options for patients with PEL are limited. Oncolytic viruses have been engineered as anticancer agents and have recently shown increased therapeutic promise. Similarly, lytic activation of endogenous viruses from latently infected tumor cells can also be applied as a cancer therapy. In theory, such a therapeutic strategy would induce oncolysis by viral replication, while simultaneously stimulating an immune response to viral lytic cycle antigens. We examined the combination of the FDA-approved drug ingenol-3-angelate (PEP005) with epigenetic drugs as a rational therapeutic approach for KSHV-mediated malignancies. JQ1, a bromodomain and extra terminal (BET) protein inhibitor, in combination with PEP005, not only robustly induced KSHV lytic replication, but also inhibited IL6 production from PEL cells. Using the dosages of these agents that were found to be effective in reactivating HIV (as a means to clear latent virus with highly active antiretroviral therapy), we were able to inhibit PEL growth in vitro and delay tumor growth in a PEL xenograft tumor model. KSHV reactivation was mediated by activation of the NF-kB pathway by PEP005, which led to increased occupancy of RNA polymerase II onto the KSHV genome. RNA-sequencing analysis further revealed cellular targets of PEP005, JQ1, and the synergistic effects of both. Thus, combination of PEP005 with a BET inhibitor may be considered as a rational therapeutic approach for the treatment of PEL.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2627-2638 |
| Number of pages | 12 |
| Journal | Molecular Cancer Therapeutics |
| Volume | 16 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 1 2017 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Oncolytic reactivation of KSHV as a therapeutic approach for primary effusion lymphoma. / Zhou, Feng; Shimoda, Michiko; Olney, Laura; Lyu, Yuanzhi; Tran, Khiem; Jiang, Guochun; Nakano, Kazushi; Davis, Ryan R.; Tepper, Clifford G; Maverakis, Emanual; Campbell, Mel; Li, Yuanpei; Dandekar, Satya; Izumiya, Yoshihiro.
In: Molecular Cancer Therapeutics, Vol. 16, No. 11, 01.11.2017, p. 2627-2638.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oncolytic reactivation of KSHV as a therapeutic approach for primary effusion lymphoma
AU - Zhou, Feng
AU - Shimoda, Michiko
AU - Olney, Laura
AU - Lyu, Yuanzhi
AU - Tran, Khiem
AU - Jiang, Guochun
AU - Nakano, Kazushi
AU - Davis, Ryan R.
AU - Tepper, Clifford G
AU - Maverakis, Emanual
AU - Campbell, Mel
AU - Li, Yuanpei
AU - Dandekar, Satya
AU - Izumiya, Yoshihiro
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV) infection. Currently, treatment options for patients with PEL are limited. Oncolytic viruses have been engineered as anticancer agents and have recently shown increased therapeutic promise. Similarly, lytic activation of endogenous viruses from latently infected tumor cells can also be applied as a cancer therapy. In theory, such a therapeutic strategy would induce oncolysis by viral replication, while simultaneously stimulating an immune response to viral lytic cycle antigens. We examined the combination of the FDA-approved drug ingenol-3-angelate (PEP005) with epigenetic drugs as a rational therapeutic approach for KSHV-mediated malignancies. JQ1, a bromodomain and extra terminal (BET) protein inhibitor, in combination with PEP005, not only robustly induced KSHV lytic replication, but also inhibited IL6 production from PEL cells. Using the dosages of these agents that were found to be effective in reactivating HIV (as a means to clear latent virus with highly active antiretroviral therapy), we were able to inhibit PEL growth in vitro and delay tumor growth in a PEL xenograft tumor model. KSHV reactivation was mediated by activation of the NF-kB pathway by PEP005, which led to increased occupancy of RNA polymerase II onto the KSHV genome. RNA-sequencing analysis further revealed cellular targets of PEP005, JQ1, and the synergistic effects of both. Thus, combination of PEP005 with a BET inhibitor may be considered as a rational therapeutic approach for the treatment of PEL.
AB - Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV) infection. Currently, treatment options for patients with PEL are limited. Oncolytic viruses have been engineered as anticancer agents and have recently shown increased therapeutic promise. Similarly, lytic activation of endogenous viruses from latently infected tumor cells can also be applied as a cancer therapy. In theory, such a therapeutic strategy would induce oncolysis by viral replication, while simultaneously stimulating an immune response to viral lytic cycle antigens. We examined the combination of the FDA-approved drug ingenol-3-angelate (PEP005) with epigenetic drugs as a rational therapeutic approach for KSHV-mediated malignancies. JQ1, a bromodomain and extra terminal (BET) protein inhibitor, in combination with PEP005, not only robustly induced KSHV lytic replication, but also inhibited IL6 production from PEL cells. Using the dosages of these agents that were found to be effective in reactivating HIV (as a means to clear latent virus with highly active antiretroviral therapy), we were able to inhibit PEL growth in vitro and delay tumor growth in a PEL xenograft tumor model. KSHV reactivation was mediated by activation of the NF-kB pathway by PEP005, which led to increased occupancy of RNA polymerase II onto the KSHV genome. RNA-sequencing analysis further revealed cellular targets of PEP005, JQ1, and the synergistic effects of both. Thus, combination of PEP005 with a BET inhibitor may be considered as a rational therapeutic approach for the treatment of PEL.
UR - http://www.scopus.com/inward/record.url?scp=85032785372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032785372&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-17-0041
DO - 10.1158/1535-7163.MCT-17-0041
M3 - Article
C2 - 28847988
AN - SCOPUS:85032785372
VL - 16
SP - 2627
EP - 2638
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
SN - 1535-7163
IS - 11
ER -